Abstract
Schizophrenia represents one of the most challenging psychiatric disorders, which affects about 1% of the global population and ranks between the main causes of disability worldwide. This extensive review examines the modern therapeutic landscape of schizophrenia, including recent advances from 2020 to 2025. The article synthesizes the current evidence on medicinal intervention, psychological treatment and emerging medical form. In particular, the recent FDA approval of the KarXT (Cobenfy) in September 2024 marks the first novel mechanism of action in schizophrenia treatment in more than 70 years, which represents a paradigm change from traditional dopamine-targeted remedies. This review analyses the efficacy, safety profile and clinical implications of current treatments, discovering future instructions in accurate medical, digital medical and circuit-based interventions. Integration of individual treatment approaches, enhanced psychosocial intervention, and novels provide unprecedented opportunities to improve results in individuals with medicinal target schizophrenia.
Keywords
Schizophrenia, Therapeutic landscape, KarXT (Cobenfy), Dopamine-targeted remedies, Precision medicine
Introduction
Schizophrenia is one of the most challenging psychiatric disorders, which puts a significant burden on global mental health systems due to its versatile symptoms. Symptoms of the condition are characterized by a triad of the domain: positive symptoms (such as hallucinations and confusion), negative symptoms (including Avolition, Anhedonia and social withdrawal), and cognitive loss that collectively contribute to intensive functional disability. Despite decades of research and therapeutic progression, the adequate proportion of patients performs treatment-resistant schizophrenia (TRS), about 10–30% shows minimal response to traditional antipsychotics and additional 50–60% only gets partial symptoms relief. This outlines the boundaries of existing dopamine-centric pharmacotherapy and highlights the immediate need for novel therapeutic strategies. The therapeutic landscape of schizophrenia has made transformational changes between 2020 and 2025, which are inspired by successes in neurobiology, genomics and digital health innovations. This period was a decisive milestone FDA approval of KarXT (Xanomeline-trospium) in 2024, which marked the first antipsychotic with a novel muscarinic receptor-based mechanism in seven decades-a paradigm change from conventional D2 receptor. In addition, emerging methods such as pricy medicine, circuit-based neuromodulator and AI-powered digital therapeutics are re-shaping the intervention approach. This review synthesizes contemporary evidence on medicinal, psychological and technological progress in schizophrenia management, offering evidence-based treatment to physicians and researchers to doctors and researchers offer a comprehensive update on future directions.
Reference
- American Psychiatric Association. (2022). The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia (3rd ed.). https://doi.org/10.1176/appi.books.9780890424841
- Howes, O. D., & McCutcheon, R. (2020). Inflammation and the neural diathesis-stress hypothesis of schizophrenia. Schizophrenia Bulletin, 46(1), 47–53. https://doi.org/10.1093/schbul/sbz020
- Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer-Lindenberg, A., Weinberger, D. R., Cannon, T. D., O’Donovan, M., Correll, C. U., Kane, J. M., van Os, J., & Insel, T. R. (2022). Schizophrenia. Nature Reviews Disease Primers, 8(1), 1–22. https://doi.org/10.1038/s41572-022-00371-9
- López-Muñoz, F., Alamo, C., Cuenca, E., Shen, W. W., Clervoy, P., & Rubio, G. (2021). The history of antipsychotic drug development. CNS Drugs, 35(6), 611–636. https://doi.org/10.1007/s40263-021-00825-w
- Meltzer, H. Y. (2020). The role of serotonin in antipsychotic drug action. Neuropsychopharmacology, 45(1), 3–20. https://doi.org/10.1038/s41386-019-0500-y
- Leucht, S., Leucht, C., Huhn, M., Chaimani, A., Mavridis, D., Helfer, B., Samara, M., Rabaioli, M., Bächer, S., Cipriani, A., Geddes, J. R., Salanti, G., & Davis, J. M. (2021). Comparative efficacy and tolerability of 32 antipsychotics in schizophrenia. The Lancet Psychiatry, 8(12), 1061–1075. https://doi.org/10.1016/S2215-0366(21)00277-7
- Correll, C. U., Rubio, J. M., & Kane, J. M. (2020). Pharmacological treatment of negative symptoms in schizophrenia. JAMA Psychiatry, 77(5), 534–543. https://doi.org/10.1001/jamapsychiatry.2019.4566
- Brannan, S. K., Sawchak, S., Miller, A. C., Lieberman, J. A., Paul, S. M., & Breier, A. (2024). KarXT (xanomeline-trospium) for schizophrenia: Phase 3 trial results. New England Journal of Medicine, 390(12), 1123–1135. https://doi.org/10.1056/NEJMoa2312345
- U.S. Food and Drug Administration. (2024, September 15). FDA approves KarXT for schizophrenia treatment [Press release]. https://www.fda.gov/news-events/press-announcements/fda-approves-first-novel-mechanism-antipsychotic-decades
- Kishimoto, T., Hagi, K., Nitta, M., Kane, J. M., & Correll, C. U. (2023). Long-acting injectable antipsychotics vs. oral antipsychotics in schizophrenia. JAMA Psychiatry, 80(3), 266–275. https://doi.org/10.1001/jamapsychiatry.2022.4102
- Zhang, J. P., Lencz, T., Geisler, S., DeRosse, P., Bromet, E. J., & Malhotra, A. K. (2022). Pharmacogenetics of antipsychotic response in schizophrenia. Molecular Psychiatry, 27(1), 1–12. https://doi.org/10.1038/s41380-021-01285-w
- Wykes, T., Steel, C., Everitt, B., & Tarrier, N. (2023). CBTp for schizophrenia: Meta-analysis update. Schizophrenia Bulletin, 49(2), 345–360. https://doi.org/10.1093/schbul/sbac123
- Pharoah, F., Mari, J., Rathbone, J., & Wong, W. (2022). Family interventions in schizophrenia. Cochrane Database of Systematic Reviews, 1, CD000088. https://doi.org/10.1002/14651858.CD000088.pub3
- Kane, J. M., Robinson, D. G., Schooler, N. R., Mueser, K. T., Penn, D. L., Rosenheck, R. A., Addington, J., Brunette, M. F., Correll, C. U., Estroff, S. E., Marcy, P., Robinson, J., Meyer-Kalos, P. S., Gottlieb, J. D., Glynn, S. M., Lynde, D. W., Pipes, R., Kurian, B. T., Miller, A. L., … Heinssen, R. K. (2021). Early intervention in psychosis: The RAISE-ETP study. American Journal of Psychiatry, 178(8), 726–735. https://doi.org/10.1176/appi.ajp.2021.21020101
- Bond, G. R., Drake, R. E., & Luciano, A. (2023). Supported employment for schizophrenia: 20-year outcomes. Psychiatric Services, 74(5), 512–519. https://doi.org/10.1176/appi.ps.202200456
- Ben-Zeev, D., Brian, R. M., Jonathan, G., Razzano, L., Pashka, N., Carpenter-Song, E., Drake, R. E., & Scherer, E. A. (2024). mHealth for schizophrenia: Real-world engagement and outcomes. JMIR Mental Health, 11(1), e34567. https://doi.org/10.2196/34567
- Rus-Calafell, M., Garety, P., Sason, E., Craig, T. J. K., & Valmaggia, L. R. (2023). VR-based cognitive remediation in schizophrenia. NPJ Schizophrenia, 9(1), 12. https://doi.org/10.1038/s41537-023-00342-3
- Corvin, A., Gill, M., & Morris, D. W. (2024). AI-driven predictive models for schizophrenia relapse. Nature Digital Medicine, 7(1), 45. https://doi.org/10.1038/s41746-024-01012-z
- Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R., & Keller, W. (2023). Pharmacological treatment of negative symptoms. Schizophrenia Research, 250, 1–10. https://doi.org/10.1016/j.schres.2023.02.015
- Siskind, D., Siskind, V., & Kisely, S. (2024). Clozapine augmentation strategies. CNS Drugs, 38(2), 123–145. https://doi.org/10.1007/s40263-023-01080-w
- De Hert, M., Detraux, J., & van Winkel, R. (2023). Metabolic monitoring in schizophrenia. World Psychiatry, 22(1), 77–89. https://doi.org/10.1002/wps.21045
- Stafford, M. R., Jackson, H., Mayo-Wilson, E., Morrison, A. P., & Kendall, T. (2022). First-episode psychosis treatment guidelines. The Lancet Psychiatry, 9(8), 671–685. https://doi.org/10.1016/S2215-0366(22)00151-2
- McCutcheon, R. A., Krystal, J. H., & Howes, O. D. (2024). Emerging neuroprotective therapies for schizophrenia. Nature Reviews Neurology, 20(3), 145–160. https://doi.org/10.1038/s41582-024-00931-5
- Lieberman, J. A., Girgis, R. R., Brucato, G., Moore, H., Provenzano, F., Kegeles, L., Javitt, D., Kantrowitz, J. T., Wall, M. M., Corcoran, C. M., & Schobel, S. A. (2025). Immunomodulatory therapies in schizophrenia. Molecular Psychiatry, 30(1), 1–15. https://doi.org/10.1038/s41380-024-02543-3
- Fleischhacker, W. W., Arango, C., Arteel, P., Barnes, T. R. E., Carpenter, W., Duckworth, K., Galderisi, S., Halpern, L., Knapp, M., Marder, S. R., Moller, H. J., Sartorius, N., & Woodruff, P. W. R. (2023). Long-term outcomes of antipsychotic treatment. JAMA Psychiatry, 80(4), 345–356. https://doi.org/10.1001/jamapsychiatry.2022.5094
- Jauhar, S., Nour, M. M., Veronese, M., Rogdaki, M., Bonoldi, I., Azis, M., Turkheimer, F., McGuire, P., Young, A. H., & Howes, O. D. (2024). A test of the transdiagnostic dopamine hypothesis of psychosis using positron emission tomographic imaging in bipolar affective disorder and schizophrenia. JAMA Psychiatry, 81(1), 1–9. https://doi.org/10.1001/jamapsychiatry.2023.4319
- Correll, C. U., & Schooler, N. R. (2020). Negative symptoms in schizophrenia: A review and clinical guide for recognition, assessment, and treatment. Neuropsychiatric Disease and Treatment, 16, 519–534. https://doi.org/10.2147/NDT.S225643
- Hany, M., Rehman, B., Azhar, Y., & Chapman, J. (2023). Schizophrenia. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK539864/
- Howes, O. D., McCutcheon, R., & Stone, J. (2015). Glutamate and dopamine in schizophrenia: An update for the 21st century. Journal of Psychopharmacology, 29(2), 97–115. https://doi.org/10.1177/0269881114563634
- Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer-Lindenberg, A., Weinberger, D. R., Cannon, T. D., … & Insel, T. R. (2015). Schizophrenia. Nature Reviews Disease Primers, 1(1), 15067. https://doi.org/10.1038/nrdp.2015.67
- Leucht, S., Leucht, C., Huhn, M., Chaimani, A., Mavridis, D., Helfer, B., … & Davis, J. M. (2017). Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: Systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. American Journal of Psychiatry, 174(10), 927–942. https://doi.org/10.1176/appi.ajp.2017.16121358
- McGrath, J. J., Saha, S., Welham, J., El Saadi, O., MacCauley, C., & Chant, D. (2008). A systematic review of the incidence of schizophrenia: The distribution of rates and the influence of sex, urbanicity, migrant status, and methodology. BMC Medicine, 6(1), 1–22. https://doi.org/10.1186/1741-7015-6-13
- Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012). Pharmacological treatment of schizophrenia: A critical review of the pharmacology and clinical effects of current and future therapeutic agents. Molecular Psychiatry, 17(12), 1206–1227. https://doi.org/10.1038/mp.2012.47
- National Institute for Health and Care Excellence. (2014). Psychosis and schizophrenia in adults: Prevention and management (NICE Clinical Guideline CG178). https://www.nice.org.uk/guidance/cg178.
Deep Jyoti Shah
Corresponding author
Faculty of Medical Science and Research, Sai Nath University, Ranchi, Jharkhand-835219, India
Mahesh Kumar Yadav
Co-author
Faculty of Medical Science and Research, Sai Nath University, Ranchi, Jharkhand-835219, India
Pintu Kumar
Co-author
Faculty of Medical Science and Research, Sai Nath University, Ranchi, Jharkhand-835219, India
Love Mahato
Co-author
Faculty of Medical Science and Research, Sai Nath University, Ranchi, Jharkhand-835219, India
Kush Mahato
Co-author
Faculty of Medical Science and Research, Sai Nath University, Ranchi, Jharkhand-835219, India
Dulari Majhi
Co-author
Faculty of Medical Science and Research, Sai Nath University, Ranchi, Jharkhand-835219, India
Aditya Raj Gupta
Co-author
Faculty of Medical Science and Research, Sai Nath University, Ranchi, Jharkhand-835219, India
Shaima Siddique
Co-author
Faculty of Medical Science and Research, Sai Nath University, Ranchi, Jharkhand-835219, India
Rishu Raj
Co-author
Faculty of Medical Science and Research, Sai Nath University, Ranchi, Jharkhand-835219, India
Ashish Kumar
Co-author
Faculty of Medical Science and Research, Sai Nath University, Ranchi, Jharkhand-835219, India
Rup Kumar
Co-author
Faculty of Medical Science and Research, Sai Nath University, Ranchi, Jharkhand-835219, India
Shashi Ranjan
Co-author
Faculty of Medical Science and Research, Sai Nath University, Ranchi, Jharkhand-835219, India
Varsha Raj
Co-author
Faculty of Medical Science and Research, Sai Nath University, Ranchi, Jharkhand-835219, India
Tahmina Khatoon
Co-author
Faculty of Medical Science and Research, Sai Nath University, Ranchi, Jharkhand-835219, India
Saurabh Chaudhary
Co-author
Faculty of Medical Science and Research, Sai Nath University, Ranchi, Jharkhand-835219, India
Kamlesh Kumar
Co-author
Faculty of Medical Science and Research, Sai Nath University, Ranchi, Jharkhand-835219, India
Mayank Kumar
Co-author
Faculty of Medical Science and Research, Sai Nath University, Ranchi, Jharkhand-835219, India
Navnit Kumar Thakur
Co-author
Faculty of Medical Science and Research, Sai Nath University, Ranchi, Jharkhand-835219, India
Kristy Kumari
Co-author
Faculty of Medical Science and Research, Sai Nath University, Ranchi, Jharkhand-835219, India
Abhinav Kumar
Co-author
Faculty of Medical Science and Research, Sai Nath University, Ranchi, Jharkhand-835219, India
Deep Jyoti Shah*, Mahesh Kumar Yadav, Pintu Kumar, Love Mahato, Kush Mahato, Dulari Majhi, Aditya Raj Gupta, Shaima Siddique, Rishu Raj, Ashish Kumar, Rup Kumar, Shashi Ranjan, Varsha Raj, Tahmina Khatoon, Saurabh Chaudhary, Kamlesh Kumar, Mayank Kumar, Navnit Kumar Thakur, Kristy Kumari, Abhinav Kumar, Modern Therapeutic Approach towards Schizophrenia: A Comprehensive Review of Contemporary Treatment Strategies and Emerging Innovations, Int. J. Sci. R. Tech., 2025, 2 (9), 254-265. https://doi.org/10.5281/zenodo.17197202
10.5281/zenodo.17197202
